Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 mild to moderate meta-analysis

Pandit, 2021
 
CTRI/2020/06/026087
RCTpegylated interferon-α2bstandard of careCOVID-19 mild to moderatesome concern
20/20 suggested -5%
Shashi Bhushan, 2021
 
CTRI/2020/12/029855
RCTpegylated interferon-α2bstandard of careCOVID-19 mild to moderatesome concern
120/130 safety concern 305% -29%
Fu, 2020
 
ChiCTR2000030262
RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 conclusif 0%
Jagannathan, 2020
 
NCT04331899
RCTpeginterferonplaceboCOVID-19 mild to moderatesome concern
60/60 inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).